Watching this from Ukraine, where the same argument is running with none of the American context.
Two observations from twenty years of clinical work at a rehabilitation centre outside Kyiv, offered as observation and not as data.
First, the part of Berenson's case that matches what we see is not the violence claim, which I am not competent to judge, but the effect on motivation in adolescents and young adults. The young men who come to us after years of cannabis rarely arrive psychotic. They arrive flat. No goals, no tolerance for difficulty, no pleasure from real achievement. In our clinical tradition that has a name, amotivational syndrome, and whatever one thinks of the term, the picture in the room is consistent.
Second, the caveat that people in treatment should say out loud more often: we only ever see the selected tail. Those for whom cannabis was uneventful never walk into a rehabilitation centre. That does not make the harm imaginary, but it does mean neither side of this debate should generalise from clinical impressions alone.
Where the argument goes wrong in our country is the framing of light versus heavy drugs. For an addiction specialist the weight of the molecule is the wrong axis. What matters is what a substance does to the motivational system of a person who is still building one. Almost nobody we treat started with opioids or stimulants. They started with something everyone around them called harmless and controllable.
Watching this from Ukraine, where the same argument is running with none of the American context.
Two observations from twenty years of clinical work at a rehabilitation centre outside Kyiv, offered as observation and not as data.
First, the part of Berenson's case that matches what we see is not the violence claim, which I am not competent to judge, but the effect on motivation in adolescents and young adults. The young men who come to us after years of cannabis rarely arrive psychotic. They arrive flat. No goals, no tolerance for difficulty, no pleasure from real achievement. In our clinical tradition that has a name, amotivational syndrome, and whatever one thinks of the term, the picture in the room is consistent.
Second, the caveat that people in treatment should say out loud more often: we only ever see the selected tail. Those for whom cannabis was uneventful never walk into a rehabilitation centre. That does not make the harm imaginary, but it does mean neither side of this debate should generalise from clinical impressions alone.
Where the argument goes wrong in our country is the framing of light versus heavy drugs. For an addiction specialist the weight of the molecule is the wrong axis. What matters is what a substance does to the motivational system of a person who is still building one. Almost nobody we treat started with opioids or stimulants. They started with something everyone around them called harmless and controllable.
I set out that position at length in the context of the Ukrainian legalisation debate here: https://ninarkotikam.com/ru/kazarian-legalizatsiya-kanabisa/ It is in Russian, browser translation handles it adequately.
Grateful this forum exists. Pavlo Kazarian, clinical psychologist and addiction specialist, Dzherelo rehabilitation centre, Ukraine.